04-Jan-16 The Chinese government has been easing the strict regulatory process for foreign investment in the healthcare sector, and has set a goal for private hospital services to increase their contribution to the sector. As quality of care and long waiting times are significant issues for public healthcare providers, private players have an opportunity to grow thanks to their strong international branding. [image: Singapore Business Review]

 Webinars

24-Dec-15 China's public insurance coverage is far less than adequate with low reimbursement rates – patented medicine and use of high-end medical devices are usually not covered. These gaps, together with China’s effort to boost investment in private healthcare insurance, have opened up attractive opportunities for foreign insurance companies, as the sector grows at over 40% annually. [image: China Briefing]

22-Dec-15 iKang Healthcare Group, China's largest private preventive healthcare provider, announced it has acquired 70% interest of Xi'an iKang Health Management, which owns three medical centers under the brand name Xi'an INLUNG. This marks iKang's first steps into Xi'an, capital of Shaanxi Province. [image: Sapphire Healthcare]

16-Dec-15 AstraZeneca aims to build up its already strong position in China by making and developing more medicines locally, and will invest more than USD800 mn in the country over the next 10 years. The British drugmaker's decision to step up investment, notably through a strategic alliance with WuXi AppTec, chimes with Beijing's desire to see more treatments made in China. [image: China Daily]